BTAI

BioXcel Therapeutics, Inc. is a biopharmaceutical company that develops medicines in neuroscience and immuno-oncology using artificial intelligence. The company focuses on leveraging existing approved drugs and clinically evaluated product candidates to identify new therapeutic indications, aiming to reduce development costs and timelines while increasing the likelihood of success. Its clinical-stage subsidiary, OnkosXcel Therapeutics, is dedicated to advancing therapies in immuno-oncology. BioXcel targets diseases with significant unmet medical needs and large market opportunities.